Results 71 to 80 of about 61,475 (266)

Current Evidence on Best Practice Dental Survivorship Care for People With Head and Neck Cancer: An Overview of Systematic Reviews and Emerging Evidence

Head &Neck, EarlyView.
ABSTRACT Introduction Head and neck cancer (HNC) survival is improving, increasing the need to address long‐term survivorship issues. Dental survivorship—care before, during, and after treatment—remains inconsistent across services. We conducted a review of systematic reviews and emerging evidence to inform contemporary dental survivorship care for HNC
David G. Tighe, Rebecca Venchiarutti, Isidoro Ruisi, Purnima Sundaresan   +3 more
wiley   +1 more source

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial

BMC Medicine
Background We aimed to evaluate the efficacy and safety of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) plus TPC chemotherapy (NAB-paclitaxel, cisplatin or lobaplatin, and capecitabine) in patients with recurrent or metastatic nasopharyngeal ...
Yaofei Jiang, Weixin Bei, Lin Wang, Nian Lu, Cheng Xu, Hu Liang, Liangru Ke, Yanfang Ye, Shuiqing He, Shuhui Dong, Qin Liu, Chuanrun Zhang, Xuguang Wang, Weixiong Xia, Chong Zhao, Ying Huang, Yanqun Xiang, Guoying Liu   +17 more
doaj   +1 more source

The Addition of Concurrent Immune Checkpoint Inhibitors for Chemoradiotherapy With Consolidative Immune Checkpoint Inhibitors in Unresectable Cancers: A Systematic Review and Meta‐Analysis

International Journal of Cancer, EarlyView.
Currently, there are at least 30 ongoing clinical trials in the enrollment phase to evaluate adding concurrent ICIs to the PACIFIC regimen for a variety of solid tumors. Considering the lack of head‐to‐head comparative studies, this meta‐analysis aims to investigate the differences in efficacy between adding and not adding concurrent ICIs to CRT ...
Xu Tong, Zhenting Liu, Xiaoxiang Zhou, Nan Bi, Yibo Gao   +4 more
wiley   +1 more source

Efficacy of metastasis-directed therapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy and local regional radiotherapy: a multicenter retrospective study

BMC Cancer
Objective To develop a prognostic model that predicts outcomes and identifies ideal candidates for metastasis-directed therapy (MDT) in patients with de novo metastatic nasopharyngeal carcinoma (dmNPC) after chemo-immunotherapy and locoregional ...
Shui-Qing He, Shu-Hui Lv, Si-Qing Wen, Lin Wang, Ya-Hui Yu, Guo-Yi Zhang, Ding-Sheng Peng, Wei-Xin Bei, Chun-Lan Chen, Ze-Yu Zhao, Ying Huang, Yan-Qun Xiang, Guo-Ying Liu   +12 more
doaj   +1 more source

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, EarlyView.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source

Hypervision Proton Surgery: The Future Direction of Proton Therapy

iNew Medicine, EarlyView.
ABSTRACT Proton beams provide unique physical advantages characterized by a low entrance dose, negligible exit dose, and a sharp Bragg peak, which enable superior sparing of normal tissues and support safe dose escalation for improved tumor control. However, conventional photon‐based fractionation remains widely used in proton therapy, where prolonged ...
Li Li, Shuanghu Yuan
wiley   +1 more source

Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy

Scientific Reports
To assess the efficacy and safety of the combination of immune checkpoint inhibitors (ICIs) and target therapy (anti-angiogenesis or EGFR inhibitors) as a second-line or subsequent treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC),
Yaofei Jiang, Chun Chen, Guoying Liu, Ting Fang, Nian Lu, Weixin Bei, Shuhui Dong, Wangzhong Li, Weixiong Xia, Hu Liang, Yanqun Xiang   +10 more
doaj   +1 more source

Diet and nasopharyngeal carcinoma [PDF]

FEMS Microbiology Letters, 1990
Nasopharyngeal carcinoma (NPC) is a disease with a remarkable racial and geographical distribution. It is very rare (incidence of less than 1 per 100,000 person-years) in most parts of the world and only a handful of populations are known to deviate from this low-risk profile, which include people of southern China.
openaire   +3 more sources

The Endothelial CXCR Family in Vascular Health and Disease

iNew Medicine, EarlyView.
ABSTRACT Endothelial cells (ECs) form the dynamic interface between blood and tissue, serving as key regulators of vascular homeostasis, inflammation, and repair. Among the molecular systems governing endothelial behavior, the C‐X‐C motif chemokine receptor (CXCR) family—originally characterized in immunology for its roles in leukocyte trafficking and ...
Zhiming Wu, Yandi Wu, Suowen Xu, Yu Huang, Li Wang   +4 more
wiley   +1 more source

Nasopharyngeal Carcinoma [PDF]

Head and Neck Pathology, 2012
Laura N, Carle, Charles C, Ko, James T, Castle   +2 more
openaire   +2 more sources